Remo Panaccione

61.1k total citations · 23 hit papers
704 papers, 36.7k citations indexed

About

Remo Panaccione is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Remo Panaccione has authored 704 papers receiving a total of 36.7k indexed citations (citations by other indexed papers that have themselves been cited), including 589 papers in Genetics, 435 papers in Epidemiology and 208 papers in Surgery. Recurrent topics in Remo Panaccione's work include Inflammatory Bowel Disease (589 papers), Microscopic Colitis (387 papers) and Eosinophilic Esophagitis (104 papers). Remo Panaccione is often cited by papers focused on Inflammatory Bowel Disease (589 papers), Microscopic Colitis (387 papers) and Eosinophilic Esophagitis (104 papers). Remo Panaccione collaborates with scholars based in Canada, United States and United Kingdom. Remo Panaccione's co-authors include Subrata Ghosh, Gilaad G. Kaplan, William J. Sandborn, Eric I. Benchimol, Paul Rutgeerts, Herman W. Barkema, Siew C. Ng, Brian G. Feagan, Richard N. Fedorak and Stefan Schreiber and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Remo Panaccione

654 papers receiving 35.9k citations

Hit Papers

Worldwide incidence and p... 2002 2026 2010 2018 2017 2011 2006 2006 2012 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
    2017 4.3k citations Siew C. Ng, Remo Panaccione et al. profile →
  2. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
    2011 3.7k citations Remo Panaccione, Subrata Ghosh et al. Gastroenterology profile →
  3. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
    2006 1.7k citations William J. Sandborn, Paul Rutgeerts et al. Gastroenterology profile →
  4. Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
    2006 1.3k citations Stephen B. Hanauer, William J. Sandborn et al. Gastroenterology profile →
  5. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
    2012 838 citations William J. Sandborn, Bruce E. Sands et al. profile →
  6. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
    2007 798 citations William J. Sandborn, P. Rutgeerts et al. Gut profile →
  7. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
    2019 787 citations Bruce E. Sands, William J. Sandborn et al. profile →
  8. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
    2007 740 citations William J. Sandborn, Paul Rutgeerts et al. profile →
  9. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota
    2002 736 citations Edward V. Loftus, Remo Panaccione et al. Gastroenterology profile →
  10. Natalizumab Induction and Maintenance Therapy for Crohn's Disease
    2005 688 citations William J. Sandborn, Jean‐Frédéric Colombel et al. profile →
  11. Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
    2013 685 citations Remo Panaccione, Subrata Ghosh et al. Gastroenterology profile →
  12. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
    2011 683 citations William J. Sandborn, Stephen B. Hanauer et al. Gut profile →
  13. Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies
    2013 632 citations Remo Panaccione, Subrata Ghosh et al. Gastroenterology profile →
  14. Crohn’s disease
    2020 631 citations Siew C. Ng, Paulo Gustavo Kotze et al. profile →
  15. The safety of vedolizumab for ulcerative colitis and Crohn's disease
    2016 563 citations Jean‐Frédéric Colombel, Bruce E. Sands et al. Gut profile →
  16. Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host
    2011 438 citations Gilaad G. Kaplan, Paul L. Beck et al. profile →
  17. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
    2012 433 citations Remo Panaccione et al. profile →
  18. Association of host genome with intestinal microbial composition in a large healthy cohort
    2016 322 citations Anne M. Griffiths, Remo Panaccione et al. profile →
  19. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
    2017 296 citations Julián Panés, William J. Sandborn et al. Gut profile →
  20. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
    2016 289 citations Stephan R. Targan, Brian G. Feagan et al. profile →
  21. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
    2023 218 citations Edward V. Loftus, Julián Panés et al. profile →
  22. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis
    2021 174 citations Remo Panaccione, William J. Sandborn et al. profile →
  23. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
    2022 132 citations William J. Sandborn, Geert D’Haens et al. Gastroenterology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Remo Panaccione 26.4k 19.4k 10.1k 8.2k 4.4k 704 36.7k
Bruce E. Sands 28.6k 1.1× 20.9k 1.1× 10.8k 1.1× 9.9k 1.2× 4.5k 1.0× 596 39.6k
Gert Van Assche 26.9k 1.0× 20.6k 1.1× 10.7k 1.1× 8.9k 1.1× 3.2k 0.7× 476 36.8k
Geert D’Haens 31.3k 1.2× 24.1k 1.2× 12.3k 1.2× 8.5k 1.0× 4.0k 0.9× 913 43.0k
Stephen B. Hanauer 25.5k 1.0× 19.0k 1.0× 9.0k 0.9× 8.8k 1.1× 2.8k 0.6× 159 33.6k
Laurent Peyrin‐Biroulet 34.1k 1.3× 25.1k 1.3× 13.3k 1.3× 9.9k 1.2× 6.4k 1.4× 1.2k 49.9k
Subrata Ghosh 17.1k 0.6× 12.2k 0.6× 8.5k 0.8× 5.9k 0.7× 5.1k 1.1× 590 31.0k
Stephan R. Targan 18.3k 0.7× 12.5k 0.6× 6.0k 0.6× 11.5k 1.4× 4.4k 1.0× 434 31.0k
Edward V. Loftus 26.3k 1.0× 21.5k 1.1× 13.7k 1.4× 4.8k 0.6× 2.1k 0.5× 773 37.2k
Silvio Danese 30.1k 1.1× 20.9k 1.1× 13.2k 1.3× 12.3k 1.5× 7.6k 1.7× 1.3k 50.7k
Gilaad G. Kaplan 15.7k 0.6× 13.3k 0.7× 11.2k 1.1× 4.5k 0.6× 6.2k 1.4× 486 34.2k

Countries citing papers authored by Remo Panaccione

Since Specialization
Citations

This map shows the geographic impact of Remo Panaccione's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Remo Panaccione with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Remo Panaccione more than expected).

Fields of papers citing papers by Remo Panaccione

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Remo Panaccione. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Remo Panaccione. The network helps show where Remo Panaccione may publish in the future.

Co-authorship network of co-authors of Remo Panaccione

This figure shows the co-authorship network connecting the top 25 collaborators of Remo Panaccione. A scholar is included among the top collaborators of Remo Panaccione based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Remo Panaccione. Remo Panaccione is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Quan, Meilan Xue, Anne M. Griffiths, et al.. (2025). A73 MICROBIAL CONTRIBUTION TO THE RISK OF FUTURE CROHN’S DISEASE: STRATIFICATION BY SUBCLINICAL INFLAMMATION LEVELS MEASURED BY FECAL CALPROTECTIN. Journal of the Canadian Association of Gastroenterology. 8(Supplement_1). i29–i29. 1 indexed citations
2.
Solitano, Virginia, Çharles N. Bernstein, Iris Dotan, et al.. (2025). Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response. Nature Reviews Gastroenterology & Hepatology. 22(6). 438–452. 5 indexed citations
3.
Peyrin‐Biroulet, Laurent, J F Colombel, Geert D’Haens, et al.. (2024). DOP18 Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial. Journal of Crohn s and Colitis. 18(Supplement_1). i104–i105. 2 indexed citations
4.
5.
Panaccione, Remo, Édouard Louis, Jean‐Frédéric Colombel, et al.. (2024). P593 Efficacy of Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis by Prior Advanced Therapy Failure and Mechanism of Action: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies. Journal of Crohn s and Colitis. 18(Supplement_1). i1146–i1148. 1 indexed citations
6.
Ferrante, Marc, Remo Panaccione, Jean‐Frédéric Colombel, et al.. (2024). DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension. Journal of Crohn s and Colitis. 18(Supplement_1). i167–i169. 4 indexed citations
7.
Vermeire, Séverine, Marla Dubinsky, Brian Feagan, et al.. (2024). P113 Maintenance of week 12 response through week 52 with etrasimod in patients with ulcerative colitis in ELEVATE UC 52. Poster presentations. A119.1–A119.
8.
Reinisch, Walter, Kamal Patel, Natalia Borruel, et al.. (2023). P658 Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison. Journal of Crohn s and Colitis. 17(Supplement_1). i785–i786. 2 indexed citations
9.
Sands, Bruce E., Laurent Peyrin‐Biroulet, Silvio Danese, et al.. (2023). 477a A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMISUC, COHORT 1. Gastroenterology. 164(6). S–1570. 1 indexed citations
10.
Colombel, Jean‐Frédéric, Silvio Danese, Naomi Martin, et al.. (2023). Tu1717 SAFETY PROFILE OF RISANKIZUMAB IN CROHN'S DISEASE PATIENTS BY AGE: POST-HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES. Gastroenterology. 164(6). S–1091. 1 indexed citations
11.
Verstockt, Bram, Séverine Vermeire, Laurent Peyrin‐Biroulet, et al.. (2023). The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. Journal of Crohn s and Colitis. 18(5). 762–772. 6 indexed citations
12.
Vermeire, Séverine, J F Colombel, Ken Takeuchi, et al.. (2022). DOP38 Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1. Journal of Crohn s and Colitis. 16(Supplement_1). i087–i088. 10 indexed citations
13.
Ma, Christopher, Abdulelah Almutairdi, Divine Tanyingoh, et al.. (2019). Reduction in surgical stoma rates in Crohn's disease: a population‐based time trend analysis. Colorectal Disease. 21(11). 1279–1287. 12 indexed citations
14.
Seow, Cynthia H., Yvette Leung, Niels Vande Casteele, et al.. (2017). The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 45(10). 1329–1338. 61 indexed citations
15.
Ma, Christopher, Richard N. Fedorak, Gilaad G. Kaplan, et al.. (2017). Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort. Alimentary Pharmacology & Therapeutics. 45(9). 1232–1243. 123 indexed citations
16.
Colombel, Jean‐Frédéric, William J. Sandborn, Walter Reinisch, et al.. (2017). Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Alimentary Pharmacology & Therapeutics. 47(2). 219–228. 32 indexed citations
17.
Colombel, Jean‐Frédéric, Bruce E. Sands, Paul Rutgeerts, et al.. (2016). The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 66(5). 839–851. 563 indexed citations breakdown →
18.
Gasia, Miriam Fort, Remo Panaccione, Gilaad G. Kaplan, et al.. (2015). P176. Irritable bowel syndrome frequency in Inflammatory Bowel Disease during both clinical and deep remission and its association with fecal calprotectin. Journal of Crohn s and Colitis. 9(suppl 1). S164–S165. 3 indexed citations
19.
Gasia, Miriam Fort, Remo Panaccione, Gilaad G. Kaplan, et al.. (2015). P175. Clinical outcome of ulcerative colitis with mucosal healing demonstrated by white light endoscopy but with subtle abnormalities detected by high definition iSCAN endoscopy. Journal of Crohn s and Colitis. 9(suppl 1). S164–S164. 1 indexed citations
20.
Schicho, Rudolf, Rustem Shaykhutdinov, Jennifer Ngo, et al.. (2012). Quantitative Metabolomic Profiling of Serum, Plasma, and Urine by 1 H NMR Spectroscopy Discriminates between Patients with Inflammatory Bowel Disease and Healthy Individuals. Journal of Proteome Research. 11(6). 3344–3357. 204 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bruce E. Sands Breakdown of academic impact, for papers by Gert Van Assche Breakdown of academic impact, for papers by Geert D’Haens Breakdown of academic impact, for papers by Stephen B. Hanauer Breakdown of academic impact, for papers by Laurent Peyrin‐Biroulet Breakdown of academic impact, for papers by Subrata Ghosh Breakdown of academic impact, for papers by Stephan R. Targan Breakdown of academic impact, for papers by Edward V. Loftus Breakdown of academic impact, for papers by Silvio Danese Breakdown of academic impact, for papers by Gilaad G. Kaplan
Rankless by CCL
2026